½ÃÀ庸°í¼­
»óǰÄÚµå
1799530

¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç ½ÃÀå : ½ÃÀå ±Ô¸ð ºÐ¼® - ¼ö¹ýº°, Á¦Ç°º°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)

Global Blood Culture Tests Market Size study & Forecast, by Method, Product, Technology, Application, End User and Regional Forecasts 2022-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 285 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç ½ÃÀåÀº 2024³â¿¡ ¾à 56¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025-2035³â 8.00%ÀÇ °ßÁ¶ÇÑ CAGR·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç÷¾× ¹è¾ç °Ë»ç´Â ÀÓ»ó Áø´ÜÀÇ ÇÙ½ÉÀ̸ç, Ç÷·ù °¨¿°ÀÇ Á¶±â ¹ß°ßÀ» °¡´ÉÇÏ°Ô Çϰí, Ç¥Àû Ç×±ÕÁ¦ ¿ä¹ýÀ» À¯µµÇϸç, °á±¹ ÆÐÇ÷Áõ°ú °ü·ÃµÈ »ç¸Á·üÀ» °¨¼Ò½Ãŵ´Ï´Ù. °¨¿°ÁõÀÇ ¸¸¿¬, Ç×»ýÁ¦ ³»¼º Áõ°¡, ÆÐÇ÷ÁõÀÇ ¼¼°è ºÎ´ãÀÇ Áõ´ë°¡ ´õÇØÁ®, º¸´Ù °íµµ·Î ½Å¼ÓÇϰí Á¤È®ÇÑ °Ë»ç ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ƯÈ÷ ÀÚµ¿ Ç÷¾× ¹è¾ç ½Ã½ºÅÛ ¹× ºÐÀÚÁø´Ü ±â¼úÀÇ Áøº¸´Â ½ÇÇè½Ç°ú º´¿øÀÌ ´õ ºü¸¥ ³³±â¿Í ´õ ³ôÀº °¨µµ¸¦ ´Þ¼ºÇÒ ¼ö ÀÖ°Ô ÇÏ¿© ȯÀÚ °ü¸® ÇÁ·ÎÅäÄÝÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç÷¾× ¹è¾ç °Ë»ç°¡ º´¿ø ¹× Ç¥ÁØ °Ë»ç½ÇÀÇ ÀÏ»ó Áø´Ü ÆÐ³Î¿¡ ²ÙÁØÈ÷ ÅëÇյǰí ÀÖ´Â °Íµµ ½ÃÀåÀÇ ¼ºÀå ±Ëµµ¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ º´¿ø³» °¨¿°(HAI)°ú ½Î¿ì°í ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇØ °øÁߺ¸°Ç ´ç±¹°ú ¹Î°£±â¾÷ ¸ðµÎ°¡ ³ë·ÂÀ» °­È­Çϰí ÀÖ´Ù´Â Á¡µµ ½ÃÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´ ¿¹¹æ °ü¸® ¼¾ÅÍ(CDC)¿¡ µû¸£¸é, ÆÐÇ÷ÁõÀº ¿©ÀüÈ÷ ¹Ì±¹ º´¿ø¿¡¼­ ÁÖ¿ä »ç¸Á Áß ÇϳªÀÌ¸ç ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸ÀÇ ÀÓ»ó ±ä±Þ¼ºÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È­ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿äÀÇ ±ÞÁõÀº º¸´Ù ½Å¼ÓÇÑ Áø´ÜÀÇ Çʿ伺¿¡ ´ëÀÀÇÒ »Ó¸¸ ¾Æ´Ï¶ó, ¼÷·ÃµÈ °Ë»ç±â»çÀÇ ºÎÁ·ÀÌ ½É°¢È­µÈ °á°úÀ̱⵵ Çϰí, ÀÇ·á Á¦°ø¾÷ü¸¦ °í󸮷®ÀÇ ³ëµ¿ Áý¾àÀûÀÌÁö ¾ÊÀº ¼Ö·ç¼ÇÀ¸·Î ¹Ð°í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ºÐÀÚ»ý¹°ÇÐÀ̳ª ´Ü¹éÁúüÇп¡ ±Ù°ÅÇÑ Á¢±ÙÀÇ È®´ë¿¡ ÀÇÇØ Á¾·¡ÀÇ ¹è¾ç¹ý¿¡¼­´Â ¾î·Á¿ü´ø ¹è¾ç °ï¶õÇÑ º´¿øÃ¼ÀÇ °ËÃâ¿¡µµ ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí, ¼³ºñ ºñ¿ëÀÌ ³ô°í, ÀúÀÚ¿ø ȯ°æ¿¡¼­´Â Áøº¸µÈ Áø´Ü¹ý¿¡ ´ëÇÑ ¾×¼¼½º°¡ Á¦ÇѵǾî ÀÖ´Â °Í, Ç¥ÁØÈ­µÈ ÇÁ·ÎÅäÄÝÀÌ ÇÊ¿äÇÏ´Ù´Â °Í µîÀÌ, ƯÁ¤ Áö¿ª¿¡¼­ ½ÃÀå ħÅõÀÇ Áö¼ÓÀûÀÎ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù.

Áö¸®Àû °üÁ¡¿¡¼­ ºÏ¹Ì´Â ¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ±× ¹è°æ¿¡´Â Á¤±³ÇÑ ÀÇ·á ÀÎÇÁ¶ó, ÆÐÇ÷ÁõÀÇ Á¶±â Áø´Ü¿¡ ´ëÇÑ ³ôÀº ÀÇ½Ä ¼öÁØ, Áø´Ü ±â¼ú Çõ½Å¿¡ ¸¹Àº ÅõÀÚ µîÀÌ ÀÖ½À´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ÀÓ»ó ½ÇÇè½ÇÀÇ °­·ÂÇÑ ³×Æ®¿öÅ©¿Í ÀÚµ¿ °Ë»ç ½Ã½ºÅÛÀÇ ³ôÀº µµÀÔ·üÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. À¯·´Àº ÀÇ·á Á¤Ã¥, ¾ö°ÝÇÑ °¨¿° °ü¸® ±ÔÁ¦, ȸ¿ø±¹ °£ÀÇ °øµ¿ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÈûÀÔ¾î ±× µÚ¸¦ À̾ú½À´Ï´Ù. ÇÑÆí ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·áºñ Áõ°¡, º´¿ø ³×Æ®¿öÅ© È®´ë, Áß±¹, Àεµ µî Àα¸´ë±¹¿¡¼­ÀÇ °¨¿°Áõ Áø´Ü¿¡ ´ëÇÑ °è¸ù Ȱµ¿ÀÇ È°¼ºÈ­·Î ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½ÅÈï ½ÃÀå¿¡¼­µµ °Ë»ç ´É·Â Çâ»ó, ±âÁõÀÚ Áö¿øÀ» ÅëÇÑ º¸°Ç ÇÁ·Î±×·¥, ÃֽŠÁø´Ü ±â¼úÀÇ ´Ü°èÀû µµÀÔ µîÀ¸·Î ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ¸ñÀûÀº ÃÖ±Ù ¼ö³â°£ ´Ù¾çÇÑ ºÎ¹® ¹× ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ¹àÈ÷°í ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â ºÐ¼® ´ë»ó ±¹°¡¿¡¼­ ¾÷°èÀÇ ÁúÀû ¹× ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ½ÃÀå Àü¸Á ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦ µî Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¸¶ÀÌÅ©·Î ½ÃÀåÀÇ ÀáÀçÀûÀÎ ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ »ó¼¼ÇÑ ºÎ¹®¿Í ÇÏÀ§ ºÎ¹®Àº ´ÙÀ½°ú °°½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç ½ÃÀå : ºÐ¼® ¹üÀ§ ¹× ¼ö¹ý

  • ºÐ¼® ¸ñÀû
  • ºÐ¼® ¹æ¹ý
    • ¿¹Ãø ¸ðµ¨
    • Ã¥»ó ºÐ¼®
    • ÇÏÇâ½Ä ¹× »óÇâ½Ä Á¢±Ù
  • ºÐ¼® ¼Ó¼º
  • ºÐ¼® ¹üÀ§
    • ½ÃÀå Á¤ÀÇ
    • ½ÃÀå ±¸ºÐ
  • ºÐ¼® ÀüÁ¦Á¶°Ç
    • Æ÷ÇÔ°ú Á¦¿Ü
    • Á¦ÇÑ »çÇ×
    • ºÐ¼® ´ë»ó ±â°£

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • CEO/CXOÀÇ ÀÔÀå
  • Àü·«Àû ÀλçÀÌÆ®
  • ESG ºÐ¼®
  • ÁÖ¿ä ºÐ¼® °á°ú

Á¦3Àå ¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç ½ÃÀå : ¿ªÇÐ ºÐ¼®

  • ¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç ½ÃÀåÀ» Á¿ìÇÏ´Â ½ÃÀå ¿ªÇÐ(2024-2035³â)
  • ¼ºÀå ÃËÁø¿äÀÎ
    • ÆÐÇ÷Áõ ¹× Ç÷·ù °¨¿°ÀÇ ÀÌȯÀ²ÀÇ »ó½Â-ÁÖ¿ä ÃËÁø¿äÀÎ
    • ±â¼ú Áøº¸ : ÀÚµ¿È­, ºÐÀÚ ¹× ´Ü¹éÁúüÇÐ Áø´Ü-ÁÖ¿ä ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °í¾×ÀÇ ÀÚº» ÁöÃâ°ú ¼Ò¸ðǰÀÇ Áö¼ÓÀûÀÎ ºñ¿ë-ÁÖ¿ä ¾ïÁ¦¿äÀÎ
    • ÁßÁ¶¼Òµæ Áö¿ª¿¡¼­ ¾×¼¼½º Á¦ÇÑ ¹× ÀÎÇÁ¶óÀÇ Á¦¾à-ÁÖµÈ ¾ïÁ¦¿äÀÎ
  • ±âȸ
    • ¹è¾ç °ï¶õÇÑ º´¿øÃ¼¿¡ ´ëÇÑ ½Å¼ÓÇÑ ºÐÀÚ ¹× ´Ü¹éÁúüÇÐ Ç÷§ÆûÀÇ Ã¤¿ë°ú ÅëÇÕ-ÁÖµÈ ±âȸ
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× ¶óƾ¾Æ¸Þ¸®Ä«¿¡¼­ È®´ë, ºÐ»êÇü ¹× PoC °Ë»çÀÇ Àü°³-ÁÖµÈ ±âȸ

Á¦4Àå ¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç »ê¾÷ÀÇ ºÐ¼®

  • Porter's Five Forces ºÐ¼®
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • °ø±ÞÀÚÀÇ Çù»ó·Â
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five Forces : ¿¹Ãø ¸ðµ¨(2024-2035³â)
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
    • ȯ°æÀû
    • ¹ýÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«(2025³â)
  • ½ÃÀå Á¡À¯À² ºÐ¼®(2024-2025³â)
  • ¼¼°èÀÇ °¡°Ý ºÐ¼® ¹× µ¿Çâ(2025³â)
  • ¾Ö³Î¸®½ºÆ®ÀÇ ±Ç°í ¹× °á·Ð

Á¦5Àå ¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ¼ö¹ýº°(2025-2035³â)

  • ½ÃÀå °³¿ä
  • ¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç ½ÃÀå ½ÇÀû : ÀáÀç·Â ºÐ¼®(2025³â)
  • ±âÁ¸(¼ö¹ý)
  • ÀÚµ¿È­(±â¹ý)

Á¦6Àå ¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ¿ëµµº°(2025-2035³â)

  • ½ÃÀå °³¿ä
  • ¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç ½ÃÀå ½ÇÀû : ÀáÀç·Â ºÐ¼®(2025³â)
  • ±ÕÇ÷Áõ
  • Áø±ÕÇ÷Áõ

Á¦7Àå ¼¼°èÀÇ Ç÷¾× ¹è¾ç °Ë»ç ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : Áö¿ªº°(2025-2035³â)

  • Áö¿ª ½ÃÀå ÇöȲ
  • ÁÖ¿ä ¼±Áø±¹ ¹× ½ÅÈï±¹
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • »ç¿ìµð¾Æ¶óºñ¾Æ(KSA)
    • ³²¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï Á¤º¸

  • ÁÖ¿ä ½ÃÀåÀÇ Àü·«
  • Becton, Dickinson and Company
    • ±â¾÷ °³¿ä
    • ÁÖ¿ä °£ºÎ
    • ±â¾÷ÀÇ ½º³À¼¦
    • À繫½ÇÀû(µ¥ÀÌÅÍÀÇ À̿밡´É¼º¿¡ µû¶ó ´Ù¸§)
    • Á¦Ç° ¹× ¼­ºñ½º Æ÷Æ®Æú¸®¿À
    • ÃÖ±Ù °³¹ß
    • ½ÃÀå Àü·«
    • SWOT ºÐ¼®
  • Thermo Fisher Scientific Inc.
  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • Bruker Corporation
  • QIAGEN NV
  • Cepheid, Inc.
  • Ortho Clinical Diagnostics
  • Grifols, SA
  • Hologic, Inc.
  • Beckman Coulter, Inc.
  • Luminex Corporation
AJY 25.09.03

The Global Blood Culture Tests Market, valued at approximately USD 5.67 billion in 2024, is projected to expand at a robust CAGR of 8.00% from 2025 to 2035. Blood culture testing serves as a cornerstone in clinical diagnostics, enabling the early detection of bloodstream infections, guiding targeted antimicrobial therapy, and ultimately reducing mortality rates associated with sepsis. The increasing prevalence of infectious diseases, growing antibiotic resistance, and the rising global burden of sepsis are collectively driving demand for more sophisticated, rapid, and accurate testing methodologies. Technological advancements-particularly in automated blood culture systems and molecular diagnostics-are enabling laboratories and hospitals to achieve faster turnaround times and higher sensitivity, thereby transforming patient management protocols. Additionally, the steady integration of blood culture testing into routine diagnostic panels across hospitals and reference laboratories is strengthening the market's growth trajectory.

The market is further buoyed by intensifying efforts from both public health authorities and private players to combat hospital-acquired infections (HAIs) and improve patient outcomes. According to the Centers for Disease Control and Prevention (CDC), sepsis remains one of the leading causes of death in U.S. hospitals, underscoring the clinical urgency for reliable diagnostic tools. The surge in demand for automated systems is not only a response to the need for faster diagnosis but also a consequence of a growing shortage of skilled laboratory personnel, pushing healthcare providers toward high-throughput, less labor-intensive solutions. Simultaneously, the expansion of molecular and proteomics-based approaches is opening up avenues for detecting difficult-to-culture pathogens, which were previously a challenge for traditional culture-based methods. Nevertheless, high equipment costs, limited access to advanced diagnostics in low-resource settings, and the need for standardized protocols present ongoing challenges to market penetration in certain regions.

From a geographical standpoint, North America commands the largest share of the global blood culture tests market, driven by its sophisticated healthcare infrastructure, high awareness levels regarding early diagnosis of sepsis, and significant investments in diagnostic innovation. The United States, in particular, benefits from a strong network of clinical laboratories and high adoption rates of automated testing systems. Europe follows closely, propelled by supportive healthcare policies, stringent infection control regulations, and collaborative research initiatives across member states. Meanwhile, Asia Pacific is anticipated to exhibit the fastest growth over the forecast period, fueled by rising healthcare expenditures, expanding hospital networks, and increased awareness campaigns around infectious disease diagnostics in populous nations like China and India. Emerging markets in Latin America and the Middle East & Africa are also witnessing heightened demand, largely due to improving laboratory capabilities, donor-supported health programs, and the gradual implementation of modern diagnostic technologies.

Major market player included in this report are:

  • Becton, Dickinson and Company
  • Thermo Fisher Scientific Inc.
  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • Bruker Corporation
  • QIAGEN N.V.
  • Cepheid, Inc.
  • Ortho Clinical Diagnostics
  • Grifols, S.A.
  • Hologic, Inc.
  • Beckman Coulter, Inc.
  • Luminex Corporation

Global Blood Culture Tests Market Report Scope:

  • Historical Data - 2023, 2024
  • Base Year for Estimation - 2024
  • Forecast period - 2025-2035
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Method:

  • Conventional
  • Automated

By Product:

  • Consumables
  • Instruments

By Technology:

  • Culture
  • Molecular
  • Proteomics

By Application:

  • Bacteremia
  • Fungemia

By End User:

  • Hospitals
  • Reference Labs

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe (ROE)
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2025 to 2035.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Blood Culture Tests Market Report Scope & Methodology

  • 1.1. Research Objective
  • 1.2. Research Methodology
    • 1.2.1. Forecast Model
    • 1.2.2. Desk Research
    • 1.2.3. Top Down and Bottom-Up Approach
  • 1.3. Research Attributes
  • 1.4. Scope of the Study
    • 1.4.1. Market Definition
    • 1.4.2. Market Segmentation
  • 1.5. Research Assumption
    • 1.5.1. Inclusion & Exclusion
    • 1.5.2. Limitations
    • 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

  • 2.1. CEO/CXO Standpoint
  • 2.2. Strategic Insights
  • 2.3. ESG Analysis
  • 2.4. Key Findings

Chapter 3. Global Blood Culture Tests Market Forces Analysis

  • 3.1. Market Forces Shaping The Global Blood Culture Tests Market (2024-2035)
  • 3.2. Drivers
    • 3.2.1. Rising prevalence of sepsis and bloodstream infections (Key Driver)
    • 3.2.2. Technological advancements - automation, molecular and proteomics diagnostics (Key Driver)
  • 3.3. Restraints
    • 3.3.1. High capital expenditure and recurring consumable costs (Key Restraint)
    • 3.3.2. Limited access and infrastructure constraints in low- and middle-income regions (Key Restraint)
  • 3.4. Opportunities
    • 3.4.1. Adoption of rapid molecular/proteomics platforms and integration for difficult-to-culture pathogens (Key Opportunity)
    • 3.4.2. Expansion in Asia Pacific, Latin America and decentralized/point-of-care testing deployments (Key Opportunity)

Chapter 4. Global Blood Culture Tests Industry Analysis

  • 4.1. Porter's 5 Forces Model
    • 4.1.1. Bargaining Power of Buyer
    • 4.1.2. Bargaining Power of Supplier
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Forecast Model (2024-2035)
  • 4.3. PESTEL Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top Investment Opportunities
  • 4.5. Top Winning Strategies (2025)
  • 4.6. Market Share Analysis (2024-2025)
  • 4.7. Global Pricing Analysis And Trends 2025
  • 4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Blood Culture Tests Market Size & Forecasts by Method 2025-2035

  • 5.1. Market Overview
  • 5.2. Global Blood Culture Tests Market Performance - Potential Analysis (2025)
  • 5.3. Conventional (Method)
    • 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 5.3.2. Market size analysis, by region, 2025-2035
  • 5.4. Automated (Method)
    • 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 5.4.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Blood Culture Tests Market Size & Forecasts by Application 2025-2035

  • 6.1. Market Overview
  • 6.2. Global Blood Culture Tests Market Performance - Potential Analysis (2025)
  • 6.3. Bacteremia
    • 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 6.3.2. Market size analysis, by region, 2025-2035
  • 6.4. Fungemia
    • 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 6.4.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Blood Culture Tests Market Size & Forecasts by Region 2025-2035

  • 7.1. Blood Culture Tests Market, Regional Market Snapshot
  • 7.2. Top Leading & Emerging Countries
  • 7.3. North America Blood Culture Tests Market
    • 7.3.1. U.S. Blood Culture Tests Market
      • 7.3.1.1. Method breakdown size & forecasts, 2025-2035
      • 7.3.1.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.3.2. Canada Blood Culture Tests Market
      • 7.3.2.1. Method breakdown size & forecasts, 2025-2035
      • 7.3.2.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
  • 7.4. Europe Blood Culture Tests Market
    • 7.4.1. UK Blood Culture Tests Market
      • 7.4.1.1. Method breakdown size & forecasts, 2025-2035
      • 7.4.1.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.4.2. Germany Blood Culture Tests Market
      • 7.4.2.1. Method breakdown size & forecasts, 2025-2035
      • 7.4.2.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.4.3. France Blood Culture Tests Market
      • 7.4.3.1. Method breakdown size & forecasts, 2025-2035
      • 7.4.3.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.4.4. Spain Blood Culture Tests Market
      • 7.4.4.1. Method breakdown size & forecasts, 2025-2035
      • 7.4.4.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.4.5. Italy Blood Culture Tests Market
      • 7.4.5.1. Method breakdown size & forecasts, 2025-2035
      • 7.4.5.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.4.6. Rest of Europe Blood Culture Tests Market
      • 7.4.6.1. Method breakdown size & forecasts, 2025-2035
      • 7.4.6.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
  • 7.5. Asia Pacific Blood Culture Tests Market
    • 7.5.1. China Blood Culture Tests Market
      • 7.5.1.1. Method breakdown size & forecasts, 2025-2035
      • 7.5.1.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.5.2. India Blood Culture Tests Market
      • 7.5.2.1. Method breakdown size & forecasts, 2025-2035
      • 7.5.2.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.5.3. Japan Blood Culture Tests Market
      • 7.5.3.1. Method breakdown size & forecasts, 2025-2035
      • 7.5.3.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.5.4. Australia Blood Culture Tests Market
      • 7.5.4.1. Method breakdown size & forecasts, 2025-2035
      • 7.5.4.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.5.5. South Korea Blood Culture Tests Market
      • 7.5.5.1. Method breakdown size & forecasts, 2025-2035
      • 7.5.5.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.5.6. Rest of APAC Blood Culture Tests Market
      • 7.5.6.1. Method breakdown size & forecasts, 2025-2035
      • 7.5.6.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
  • 7.6. Latin America Blood Culture Tests Market
    • 7.6.1. Brazil Blood Culture Tests Market
      • 7.6.1.1. Method breakdown size & forecasts, 2025-2035
      • 7.6.1.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.6.2. Mexico Blood Culture Tests Market
      • 7.6.2.1. Method breakdown size & forecasts, 2025-2035
      • 7.6.2.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
  • 7.7. Middle East and Africa Blood Culture Tests Market
    • 7.7.1. UAE Blood Culture Tests Market
      • 7.7.1.1. Method breakdown size & forecasts, 2025-2035
      • 7.7.1.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.7.2. Saudi Arabia (KSA) Blood Culture Tests Market
      • 7.7.2.1. Method breakdown size & forecasts, 2025-2035
      • 7.7.2.2. Product/Technology/End User breakdown size & forecasts, 2025-2035
    • 7.7.3. South Africa Blood Culture Tests Market
      • 7.7.3.1. Method breakdown size & forecasts, 2025-2035
      • 7.7.3.2. Product/Technology/End User breakdown size & forecasts, 2025-2035

Chapter 8. Competitive Intelligence

  • 8.1. Top Market Strategies
  • 8.2. Becton, Dickinson and Company
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Financial Performance (Subject to Data Availability)
    • 8.2.5. Product/Services Port
    • 8.2.6. Recent Development
    • 8.2.7. Market Strategies
    • 8.2.8. SWOT Analysis
  • 8.3. Thermo Fisher Scientific Inc.
  • 8.4. bioMerieux SA
  • 8.5. F. Hoffmann-La Roche Ltd
  • 8.6. Abbott Laboratories
  • 8.7. Danaher Corporation
  • 8.8. Siemens Healthineers AG
  • 8.9. Bruker Corporation
  • 8.10. QIAGEN N.V.
  • 8.11. Cepheid, Inc.
  • 8.12. Ortho Clinical Diagnostics
  • 8.13. Grifols, S.A.
  • 8.14. Hologic, Inc.
  • 8.15. Beckman Coulter, Inc.
  • 8.16. Luminex Corporation
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦